A call to action — FDA encouraging development of new IBS therapies: 4 key notes

There’s a great medical need for new therapies aimed at treating irritable bowel syndrome, according to FDA gastroenterologist Tara Altepeter, MD.

Advertisement

Here’s what you should know:

1. The FDA is working at bringing more IBS-facing treatments to the market, after the emergence of new research.

2. It’s estimated that 15.3 million people or 20 percent of all Americans suffer from IBS. With unassuming symptoms, the disease often goes undiagnosed.

3. Treatments vary widely for IBS patients. For some changes in diet, nutrition and exercise can manage symptoms, while others use medication to manage their IBS. There is no cure for IBS.

4. The FDA wants to bring more treatments to the market to help the affected population better manage their IBS.

More articles on gastroenterology:
University of Arizona researchers making dual-view endoscope: 3 key notes
Payment Model Technical Advisory Committee approves Project Sonar as an alternative payment model
GI leader to know: Dr. Brent Gray of Central Texas Gastroenterology Consultants

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.